GlaxoSmithKline plans to begin production of a new vaccine for the H1N1 swine flu virus once it receives the virus seed from the WHO and said it has already received orders from a number of governments.The first doses of the vaccine are expected to be available four to six months after the virus seed has been received by the drug maker, subject to regulatory approval.GSK said Britain, France, Belgium and Finland have placed orders for close to 130m doses of the vaccine between them.